US20010008902A1 - Method for producing thiazolidinediones, and new thiazolidinediones - Google Patents
Method for producing thiazolidinediones, and new thiazolidinediones Download PDFInfo
- Publication number
- US20010008902A1 US20010008902A1 US09/783,494 US78349401A US2001008902A1 US 20010008902 A1 US20010008902 A1 US 20010008902A1 US 78349401 A US78349401 A US 78349401A US 2001008902 A1 US2001008902 A1 US 2001008902A1
- Authority
- US
- United States
- Prior art keywords
- denotes
- thiazolidine
- dione
- ethoxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *1C=C[Y]=C1.*C.CC.CC[W]C1=CC=C(CC2SC(=O)NC2=O)C2=C1C=C*2 Chemical compound *1C=C[Y]=C1.*C.CC.CC[W]C1=CC=C(CC2SC(=O)NC2=O)C2=C1C=C*2 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- A represents a carbocyclic ring with 5 or 6 carbon atoms or a heterocyclic ring with a maximum of 4 heteroatoms in which the heteroatoms can be the same or different and denote oxygen, nitrogen or sulphur and the heterocycles can optionally carry an oxygen atom on one or several nitrogen atoms,
- B denotes —CH ⁇ CH—, —N ⁇ CH—, —CH ⁇ N—, O or S,
- W denotes CH 2 , O, CH(OH), CO or —CH ⁇ CH—
- X denotes S, O or NR 2 , in which the residue R 2 is hydrogen or C 1 -C 6 alkyl,
- Y denotes CH or N
- R denotes naphthyl, pyridyl, furyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C 1 -C 3 alkyl, CF 3 , C 1 -C 3 alkoxy, F, Cl or bromine,
- R 1 denotes hydrogen or C 1 -C 6 alkyl
- n denotes 1-3
- Compounds of the general formula I can form salts with bases since they have an acidic NH group on the thiazolidinedione ring.
- Suitable pharmaceutical salts are for example alkali salts such as lithium, sodium or potassium salts, alkaline earth salts such as calcium or magnesium salts, other metal salts such as e.g. aluminium salts, ammonium salts or salts with organic bases such as e.g. diethanolamine, ethylenediamine, diisopropylamine and others.
- the sodium salt is particularly preferred.
- the salts are for example prepared by treating the compounds of the general formula (I) in a known manner with a stoichiometric amount of the corresponding base.
- the compounds are usually produced by a known process via alpha-halogenated carboxylic acids by subsequent synthesis of the thiazolidinedione ring system.
- an aromatic amino group is diazotized and the diazonium salt is reacted with ethyl acrylate in the presence of hydrohalic acid and copper salts.
- This process has some disadvantages for the production of amounts on a multi-kg scale with regard to safety, upscaling, handling and synthesis complexity.
- the aromatic amines must be diazotized to form the alpha-halogenated carboxylic acids and reacted with toxic acrylic acid ester and this reaction proceeds with unsatisfactory yields.
- a further production process according to the invention comprises the catalytic hydrogenation of compounds of the general formula II,
- A denotes CH ⁇ CH or S
- X denotes S, O or NR 2 in which the residue R 2 is hydrogen or C 1 -C 6 alkyl
- Y denotes CH or N
- R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C 1 -C 3 alkyl, CF 3 , C 1 -C 3 alkoxy, F, Cl or bromine,
- R 1 denotes hydrogen or C 1 -C 6 alkyl
- n denotes 1-3
- A, W, X, Y, R, R 1 and n have the meanings stated above with activated aluminium in a protic solvent.
- the surface of the aluminium can be activated by treatment with metal salts that are above aluminium in the electrochemical series.
- a dilute solution of mercury chloride is particularly suitable.
- the aluminium can be used in the form of chippings, grit or powder.
- Lower alcohols, in particular methanol and also water are preferably used as the protic solvent.
- Aprotic organic solvents that are miscible with alcohols or water can be added to improve the solubility or can be used as the major component.
- the reaction is carried out at 0-80° C., preferably at room temperature or a slightly increased temperature up to 40° C.
- the invention also concerns new compounds of the general formula I which are not described in the application WO 94/27995 and which, in comparison to the compounds described in this application, exhibit a surprisingly better action profile in the treatment of diabetes mellitus. These are the following compounds:
- the invention in addition concerns pharmaceutical preparations which contain the compounds listed above as an active substance for the treatment of diabetes mellitus.
- the pharmaceutical preparations are produced and used according to conventional methods described in WO 94/27995.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
in which
A denotes CH═CH or S
W denotes O
X denotes S, O or NR2 in which the residue R2 is hydrogen or C1-C6 alkyl,
Y denotes CH or N
R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine,
R1 denotes hydrogen or C1-C6 alkyl and
n denotes 1-3
in which A, W, X, Y, R, R1 and n have the meanings stated above
with activated aluminium in a protic solvent,
as well as new compounds of formula III and pharmaceutical preparations containing these compounds.
Description
-
- in which
- A represents a carbocyclic ring with 5 or 6 carbon atoms or a heterocyclic ring with a maximum of 4 heteroatoms in which the heteroatoms can be the same or different and denote oxygen, nitrogen or sulphur and the heterocycles can optionally carry an oxygen atom on one or several nitrogen atoms,
- B denotes —CH═CH—, —N═CH—, —CH═N—, O or S,
- W denotes CH2, O, CH(OH), CO or —CH═CH—,
- X denotes S, O or NR2, in which the residue R2 is hydrogen or C1-C6 alkyl,
- Y denotes CH or N
- R denotes naphthyl, pyridyl, furyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine,
- R1 denotes hydrogen or C1-C6 alkyl and
- n denotes 1-3
- as well as tautomers, enantiomers, diastereomers and physiologically tolerated salts thereof.
- Compounds of the general formula I can form salts with bases since they have an acidic NH group on the thiazolidinedione ring. Suitable pharmaceutical salts are for example alkali salts such as lithium, sodium or potassium salts, alkaline earth salts such as calcium or magnesium salts, other metal salts such as e.g. aluminium salts, ammonium salts or salts with organic bases such as e.g. diethanolamine, ethylenediamine, diisopropylamine and others. The sodium salt is particularly preferred. The salts are for example prepared by treating the compounds of the general formula (I) in a known manner with a stoichiometric amount of the corresponding base.
- The compounds are usually produced by a known process via alpha-halogenated carboxylic acids by subsequent synthesis of the thiazolidinedione ring system. In order to produce these carboxylic acids an aromatic amino group is diazotized and the diazonium salt is reacted with ethyl acrylate in the presence of hydrohalic acid and copper salts. This process has some disadvantages for the production of amounts on a multi-kg scale with regard to safety, upscaling, handling and synthesis complexity. For example in the reaction the aromatic amines must be diazotized to form the alpha-halogenated carboxylic acids and reacted with toxic acrylic acid ester and this reaction proceeds with unsatisfactory yields. Furthermore it is extremely problematic to apply this reaction to a larger scale for safety and environmental protection reasons.
-
- in which A, B, W, X, Y, R, R1 and n have the meanings stated above.
- However, the catalytic hydrogenation is very complicated. A poisoning of the catalyst by sulphur may occur especially for types of compound which, in addition to the sulphur contained in the thiazolidinedione ring, carry a further sulphur atom in the molecule which leads to very long reaction periods and requires a several-fold renewal of the catalyst.
- A further process for the reduction of compounds of the general formula II is known from the literature which comprises the use of magnesium as a reducing agent [e.g. C. C. Cantello et al., in J. Med. Chem. 37, 3977 (1994)].
- This method circumvents the interference of the catalytic process by sulphur contained in the molecule but in the case of the aforementioned compounds of the general formula II a partial reduction of the five-membered unsaturated heterocycle occurs which leads to impurities of the desired products that are difficult to separate.
- Surprisingly it has now been found that compounds of the general formula II can be smoothly reduced with a high purity by the method described last without a partial reduction of the double bonds of the five-membered heterocyclic ring system occurring if metallic aluminium is used instead of magnesium as a reducing agent, the aluminium being advantageously activated by treating the surface with salts of more noble metals.
- The process can be applied in particular to a selection of particularly valuable subclasses of the general formula I which are summarized in the following under the general formula III.
-
- in which
- A denotes CH═CH or S
- W denotes O
- X denotes S, O or NR2 in which the residue R2 is hydrogen or C1-C6 alkyl,
- Y denotes CH or N
- R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine,
- R1 denotes hydrogen or C1-C6 alkyl and
- n denotes 1-3
-
- in which A, W, X, Y, R, R1 and n have the meanings stated above with activated aluminium in a protic solvent. The surface of the aluminium can be activated by treatment with metal salts that are above aluminium in the electrochemical series. A dilute solution of mercury chloride is particularly suitable. The aluminium can be used in the form of chippings, grit or powder. Lower alcohols, in particular methanol and also water are preferably used as the protic solvent. Aprotic organic solvents that are miscible with alcohols or water can be added to improve the solubility or can be used as the major component. The reaction is carried out at 0-80° C., preferably at room temperature or a slightly increased temperature up to 40° C.
- The invention also concerns new compounds of the general formula I which are not described in the application WO 94/27995 and which, in comparison to the compounds described in this application, exhibit a surprisingly better action profile in the treatment of diabetes mellitus. These are the following compounds:
- 5-{4-[2-(5-methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- 5-{4-[2-(5-methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- 5-{4-[2-(5-methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- 5-{4-[2-(5-methyl-2-(4-trifluoromethylphenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- 5-{4-[2-(5-methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- tautomers, enantiomers, diastereomers and physiologically tolerated salts thereof.
- The invention in addition concerns pharmaceutical preparations which contain the compounds listed above as an active substance for the treatment of diabetes mellitus. The pharmaceutical preparations are produced and used according to conventional methods described in WO 94/27995.
- The following examples are intended to elucidate the new method for the production of compounds of formula (III) without limiting the method to the said special cases. The compounds of the general formula IV are produced according to the process stated in WO 94/27995.
- a) Production of Activated Aluminium
- 5 ml of a saturated solution of mercury II chloride in ethanol is diluted to 50 ml with ethanol and briefly shaken with 10 g aluminium needles. Then the solution is decanted and the needles are washed twice with ethanol, once with diethyl ether and once with tetrahydrofuran.
- b) Title Compound
- 10 g activated aluminium needles and 1 ml water are added to a solution of 2.03 g (4.3 mmol) 5-{4-[2-(5-Methyl-2-phenyloxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethylidene}-thiazolidine-2,4-dione (Fp. 204-207° C.) in 130 ml tetrahydrofuran. Then it is heated for 50 min. while stirring to 50° C. and the solid components are removed by filtration. The filtrate is evaporated and the residue is chromatographed on silica gel with a mixture of 88 parts by volume toluene, 10 parts by volume 2-butanone and 2 parts by volume glacial acetic acid. Yield: 1.65 g (83%), Fp. 204-206° C.
- The following are obtained in an analogous manner:
- a) 5-{4-[2-(5-Methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- Yield: 57%; Fp.: 115-117° C. from 5-{4-[2-(5-Methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethylidene}-thiazolidine-2,4-dione (Fp. 229-234° C.).
- b) 5-{4-[2-(5-Methyl-2-phenyloxazol-4-yl)-ethoxy]-naphth-1-ylmethyl}-thiazolidine-2,4-dione
- Yield: 76%; Fp. 187-191° C. from 5-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-naphth-1-ylmethylidene}-thiazolidine-2,4-dione (Fp.: 252-254° C.).
- c) 5-{4-[2-(5-Methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- Yield: 81%, Fp. 205° C. from 5-{4-[2-(5-Methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-yl-methylidene}-thiazolidine-2,4-dione (Fp. 240° C.).
- d) 5-{4-[2-(5-Methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- Yield: 60%, Fp. 208° C. from 5-{4-[2-(5-Methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-yl-methylidene}-thiazolidine-2,4-dione (Fp. 270° C.).
- e) 5-{4-[2-(5-Methyl-2-(4-trifluoromethylphenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- Yield: 57%; Fp. 191° C. from 5-{4-[2-(5-Methyl-2-(4-trifluoromethylphenyl)-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl-methylidene}-thiazolidine-2,4 dione (Fp. 260° C.).
- f) 5-{4-[2-(5-Methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
- Yield: 78%; Fp. 189° C. from 5-{4-[2-(5-Methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-yl-methylidene}-thiazolidine-2,4-dione (amorphous, Fp. from 255° C.)
Claims (6)
in which
A denotes CH═CH or S
W denotes O
X denotes S, O or NR2 in which the residue R2 is hydrogen or C1-C6 alkyl,
Y denotes CH or N
R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine,
R1 denotes hydrogen or C1-C6 alkyl and
n denotes 1-3
in which A, W, X, Y, R, R1 and n have the meanings stated above is reduced with metallic aluminium in a protic solvent.
2. Process as claimed in , wherein the metallic aluminium used is activated by treatment of the surfaces with salts of noble metals.
claim 1
3. Process as claimed in or , wherein the aluminium is activated with a mercury chloride solution.
claim 1
2
4. New compounds selected from the group
5-{4-[2-(5-methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
5-{4-[2-(5-methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
5-{4-[2-(5-methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
5-{4-[2-(5-methyl-2-(4-trifluoromethylphenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
5-{4-[2-(5-methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
as well as tautomers, enantiomers, diastereomers and physiologically tolerated salts thereof
5. Pharmaceutical preparation containing a compound as claimed in in addition to common carrier and auxiliary substances.
claim 4
6. Use of compounds as claimed in for the production of pharmaceutical preparations for the treatment of diabetes mellitus.
claim 4
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/783,494 US6441185B2 (en) | 1997-03-20 | 2001-02-14 | Method for producing thiazolidinediones, and new thiazolidinediones |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19711616A DE19711616A1 (en) | 1997-03-20 | 1997-03-20 | Improved process for the preparation of thiazolidinediones |
DE19711616 | 1997-03-20 | ||
US09/381,247 US6258832B1 (en) | 1997-03-20 | 1998-03-17 | Method for producing thiazolidinediones, and new thiazolidinediones |
WO98/01535 | 1998-03-17 | ||
PCT/EP1998/001535 WO1998042704A1 (en) | 1997-03-20 | 1998-03-17 | Improved method for producing thiazolidinediones, and new thiazolidinediones |
US09/783,494 US6441185B2 (en) | 1997-03-20 | 2001-02-14 | Method for producing thiazolidinediones, and new thiazolidinediones |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001535 Division WO1998042704A1 (en) | 1997-03-20 | 1998-03-17 | Improved method for producing thiazolidinediones, and new thiazolidinediones |
US09/381,247 Division US6258832B1 (en) | 1997-03-20 | 1998-03-17 | Method for producing thiazolidinediones, and new thiazolidinediones |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010008902A1 true US20010008902A1 (en) | 2001-07-19 |
US6441185B2 US6441185B2 (en) | 2002-08-27 |
Family
ID=7824011
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/381,247 Expired - Fee Related US6258832B1 (en) | 1997-03-20 | 1998-03-17 | Method for producing thiazolidinediones, and new thiazolidinediones |
US09/783,494 Expired - Fee Related US6441185B2 (en) | 1997-03-20 | 2001-02-14 | Method for producing thiazolidinediones, and new thiazolidinediones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/381,247 Expired - Fee Related US6258832B1 (en) | 1997-03-20 | 1998-03-17 | Method for producing thiazolidinediones, and new thiazolidinediones |
Country Status (26)
Country | Link |
---|---|
US (2) | US6258832B1 (en) |
EP (1) | EP0970077B1 (en) |
JP (2) | JP3484200B2 (en) |
KR (1) | KR100340353B1 (en) |
CN (1) | CN1105718C (en) |
AR (1) | AR012124A1 (en) |
AT (1) | ATE240324T1 (en) |
AU (1) | AU726048B2 (en) |
BR (1) | BR9808029A (en) |
CA (1) | CA2285208C (en) |
DE (2) | DE19711616A1 (en) |
DK (1) | DK0970077T3 (en) |
ES (1) | ES2198053T3 (en) |
HK (1) | HK1025965A1 (en) |
HU (1) | HUP0001551A3 (en) |
IL (1) | IL131772A (en) |
NO (1) | NO313292B1 (en) |
NZ (1) | NZ337608A (en) |
PL (1) | PL192201B1 (en) |
PT (1) | PT970077E (en) |
RS (1) | RS49771B (en) |
RU (1) | RU2181724C2 (en) |
TR (1) | TR199902197T2 (en) |
TW (1) | TW487707B (en) |
WO (1) | WO1998042704A1 (en) |
ZA (1) | ZA982326B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60026404T2 (en) | 1999-08-02 | 2006-10-19 | F. Hoffmann-La Roche Ag | Process for the preparation of benzothiophene derivatives |
US6531609B2 (en) | 2000-04-14 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for the preparation of thiazolidinedione derivatives |
FR2820741A1 (en) * | 2001-02-14 | 2002-08-16 | Ppg Sipsy | Pure 5-alkyl-thiazolidinedione, oxazolidinedione or hydantoin derivative preparation, for use as drug or intermediate, by reduction of corresponding alkylidene compound using formic acid |
FR2820742B1 (en) * | 2001-02-14 | 2005-03-11 | Ppg Sipsy | PROCESS FOR THE PREPARATION OF COMPOUNDS DERIVED FROM THIAZOLIDINEDIONE, OXAZOLIDINEDIONE OR HYDANTOIN |
JP2004525168A (en) * | 2001-04-06 | 2004-08-19 | エフ.ホフマン−ラ ロシュ アーゲー | Thiazolidinedione alone or in combination with other therapeutic agents to suppress or reduce tumor growth |
NZ529033A (en) | 2001-05-15 | 2005-06-24 | F | Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes |
WO2004005266A1 (en) * | 2002-07-03 | 2004-01-15 | F. Hoffmann-La Roche Ag | Oxazole derivatives and their use as insulin sensitizers |
DK1537091T3 (en) * | 2002-08-30 | 2010-11-08 | Hoffmann La Roche | New 2-arylthiazole compounds such as PPAR alpha and PPAR gamma agonists |
ATE345340T1 (en) * | 2002-09-12 | 2006-12-15 | Hoffmann La Roche | N-SUBSTITUTED-1H-INDOLE-5-PROPANE ACID COMPOUNDS AS PPAR AGONISTS FOR THE TREATMENT OF DIABETIS |
DE60323130D1 (en) * | 2002-11-25 | 2008-10-02 | Hoffmann La Roche | indole derivatives |
JP2007506671A (en) * | 2003-06-26 | 2007-03-22 | エフ.ホフマン−ラ ロシュ アーゲー | Method for producing insulin sensitizer and intermediate compound thereof |
US11796190B2 (en) | 2019-12-10 | 2023-10-24 | Lg Electronics Inc. | Air management apparatus or device |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1003445B (en) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | The preparation method of thiazolidine diketone derivative |
WO1986007056A1 (en) | 1985-05-21 | 1986-12-04 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
GB8713861D0 (en) | 1987-06-13 | 1987-07-15 | Beecham Group Plc | Compounds |
DE10199003I1 (en) | 1987-09-04 | 2003-06-12 | Beecham Group Plc | Substituted thiazolidine ion derivatives |
US5330998A (en) | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
WO1989008651A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
WO1989008650A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
WO1989008652A1 (en) | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
EP0454501B1 (en) * | 1990-04-27 | 2001-09-05 | Sankyo Company Limited | Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides |
ATE116971T1 (en) | 1990-08-23 | 1995-01-15 | Pfizer | HYPOGLYCEMIC HYDROXYUREA DERIVATIVES. |
AU3231093A (en) | 1991-12-20 | 1993-07-28 | Upjohn Company, The | A reduction method for substituted 5-methylene-thiazolidinediones |
FR2688220A1 (en) | 1992-03-06 | 1993-09-10 | Adir | NOVEL THIAZOLIDINE-2,4-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
DE4317320A1 (en) * | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | New thiazolidinediones and medicines containing them |
DK0684242T3 (en) | 1993-12-27 | 1999-11-01 | Japan Tobacco Inc | Isoxazolidinedione derivative and its use |
-
1997
- 1997-03-20 DE DE19711616A patent/DE19711616A1/en not_active Withdrawn
-
1998
- 1998-03-17 JP JP54484098A patent/JP3484200B2/en not_active Expired - Fee Related
- 1998-03-17 KR KR1019997008445A patent/KR100340353B1/en not_active IP Right Cessation
- 1998-03-17 NZ NZ337608A patent/NZ337608A/en unknown
- 1998-03-17 PT PT98916974T patent/PT970077E/en unknown
- 1998-03-17 CN CN98803388A patent/CN1105718C/en not_active Expired - Fee Related
- 1998-03-17 AT AT98916974T patent/ATE240324T1/en not_active IP Right Cessation
- 1998-03-17 CA CA002285208A patent/CA2285208C/en not_active Expired - Fee Related
- 1998-03-17 TR TR1999/02197T patent/TR199902197T2/en unknown
- 1998-03-17 RU RU99122023/04A patent/RU2181724C2/en not_active IP Right Cessation
- 1998-03-17 TW TW087103935A patent/TW487707B/en not_active IP Right Cessation
- 1998-03-17 BR BR9808029-6A patent/BR9808029A/en not_active Application Discontinuation
- 1998-03-17 RS YUP-466/99A patent/RS49771B/en unknown
- 1998-03-17 ES ES98916974T patent/ES2198053T3/en not_active Expired - Lifetime
- 1998-03-17 IL IL13177298A patent/IL131772A/en not_active IP Right Cessation
- 1998-03-17 EP EP98916974A patent/EP0970077B1/en not_active Expired - Lifetime
- 1998-03-17 HU HU0001551A patent/HUP0001551A3/en unknown
- 1998-03-17 DK DK98916974T patent/DK0970077T3/en active
- 1998-03-17 WO PCT/EP1998/001535 patent/WO1998042704A1/en active IP Right Grant
- 1998-03-17 AU AU70361/98A patent/AU726048B2/en not_active Ceased
- 1998-03-17 DE DE59808365T patent/DE59808365D1/en not_active Expired - Fee Related
- 1998-03-17 PL PL335903A patent/PL192201B1/en not_active IP Right Cessation
- 1998-03-17 US US09/381,247 patent/US6258832B1/en not_active Expired - Fee Related
- 1998-03-19 ZA ZA9802326A patent/ZA982326B/en unknown
- 1998-03-20 AR ARP980101266A patent/AR012124A1/en active IP Right Grant
-
1999
- 1999-09-17 NO NO19994505A patent/NO313292B1/en unknown
-
2000
- 2000-08-18 HK HK00105205A patent/HK1025965A1/en not_active IP Right Cessation
-
2001
- 2001-02-14 US US09/783,494 patent/US6441185B2/en not_active Expired - Fee Related
-
2003
- 2003-08-21 JP JP2003297751A patent/JP2004067697A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6258832B1 (en) | Method for producing thiazolidinediones, and new thiazolidinediones | |
US5585495A (en) | Reduction method for substituted 5-methylene-thiazolidinediones | |
EP0008203A1 (en) | Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same | |
JP2004067697A6 (en) | Novel thiazolidinedione and its use | |
CN110642803B (en) | Synthesis method of dihydrothiazole heterocyclic compound and application of dihydrothiazole heterocyclic compound in modification of biological molecules | |
AU660701B2 (en) | Process for the preparation of intermediates in the synthesis of chiral thiazolidine-2,4-dione derivatives | |
FR2965262A1 (en) | NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
SK112099A3 (en) | Process for the preparation of substituted thiazolidinedione | |
WO2014122407A2 (en) | Method for producing pyrazoles, novel pyrazoles and applications thereof | |
MXPA99008496A (en) | Improved method for producing thiazolidinediones, and new thiazolidinediones | |
CZ333999A3 (en) | Enhanced process for preparing thiazolidinediones and novel thiazolidinediones per se | |
CN104603115B (en) | The synthetic method of thiazole | |
JP2020505336A (en) | Method for producing chiral pyrrolidin-2-yl-methanol derivative | |
EP1903042A2 (en) | An improved process for hydrogenation of 5-(substituted Benzylidene) 2,4- Thiazolidine Dione compounds to give corresponding ( +/- ) 5- (substituted Benzyl ) 2,4-Thiazolidine Dione | |
FR2476081A1 (en) | 1,2,5-Thiadiazole 1-oxide and 1,1-di:oxide derivs. - useful as anti-ulcer agents | |
CZ115393A3 (en) | Process for preparing "syn" propanamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100827 |